

Supporting Information

Bioinspired radical cyclization of tryptamines: synthesis of peroxyppyrroloindolenines as potential anti-cancer agents

Yan Li, Longjie Li, Xunbo Lu, Yulong Bai, Yufan Wang, Yuzhou Wu* and Fangrui Zhong*

Hubei Key Laboratory of Bioinorganic Chemistry & Materia Medica, School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology (HUST), 1037 Luoyu road, Wuhan 430074, China
wuyuzhou@hust.edu.cn
chemzfr@hust.edu.cn

Table of contents

(A) General Information	3
(B) Reaction Condition Optimizations.....	3
(C) Representative Procedures and Analytical Data of the Desired Products	4
(D) Mass Analysis of Reaction Mixtures.....	13
(E) ^1H and ^{13}C NMR Spectra Data of All Products	15

(A) General Information


Chemicals and solvents were purchased from commercial suppliers and used as received unless noted.

All products were purified by flash chromatography on silica gel. The chemical yields referred are isolated products. ^1H NMR and ^{13}C NMR spectra were recorded on 400 MHz or 600 MHz Bruker spectrometers. Chemical shifts of ^1H NMR were reported in part per million relative to the CDCl_3 residual peak (δ 7.26). Chemical shifts of ^{13}C NMR were reported relative to CDCl_3 (δ 77.16) or CD_3OD (δ 49.00). The used abbreviations are as follows: s (singlet), d (doublet), t (triplet), quart. (quartet), quint. (quintet), m (multiplet), br (broad). Multiplets which arise from accidental equality of coupling constants of magnetically non-equivalent protons are marked as virtual (*virt.*). High resolution mass spectra (HRMS) data were measured on a ESI-microTOF II. Melting points were measured on a SGW® X-4B and are not corrected. Reactions were monitored by TLC analysis using silica gel 60 Å F-254 thin layer plates and compounds were visualized with a UV light at 254 nm or 365 nm. Further visualization was achieved by staining with iodine, or KMnO_4 followed by heating on a hot plate. Flash column chromatography was performed on silica gel 60 Å, 10–40 μm .

N-tosyl tryptamine derivatives prepared according to known literature procedures.^{1,2}

(B) Reaction Condition Optimizations

Table S1 solvent screening^a



entry	solvent	temp (°C)	yield ^b (%)
1	CH_3CN	reflux	45
2	1,4-dioxane	90	78

¹ Muratore, M. E.; Holloway, C. A.; Pilling, A. W.; Storer, R. I.; Trevitt, G.; Dixon, D. J. *J. Am. Chem. Soc.* **2009**, *131*, 10796.

² Kieffer, M. E.; Chuang, K. V.; Reisman, S. E. *Chem. Sci.* **2012**, *3*, 3170.


3	DCE	reflux	24
4	Toluene	90	34
5	THF	reflux	40
6	EtOAc	reflux	61
7	H ₂ O	90	0

^aReactions were performed with **1a** (0.2 mmol), TBAI (20 mol%), and TBHP (4.0 eq) in solvent (4.0 mL) for 2 hours. ^bIsolated yield.

(C) Representative Procedures and Analytical Data of the Desired Products

General procedure: A 50 mL round bottom flask was charged with TBAI (14.8 mg, 20 mol %), tryptamine substrates **1** (0.2 mmol, 1.0 eq) and 1,4-dioxane (4.0 mL), then TBHP (70% in wa-ter, 114.4 μ L, 0.8 mmol, 4.0 eq) was added. The reaction mixture was heat to 90 °C for 2 h before cooled down to room temperature. Saturated aqueous Na₂S₂O₃ (10 mL) solution was slowly introduced and the resulting mixture was extracted with EtOAc (3 \times 10 mL). The combined organic layers were dried over Na₂SO₄, filtered, concentrated under reduced pressure and the residue was purified by chromatography on silica gel (eluent: Hexane/EtOAc, 30:1 to 10:0) to afford peroxy-ypyrroloindolenine **2**.

3a-(*tert*-Butylperoxy)-1-tosyl-1,2,3,3a-tetrahydropyrrolo[2,3-b]indole **2a**



Compound **2a** was synthesized following the *general procedure*.

A white solid, 64.1 mg, 80% yield.

m.p.: 131 – 133 °C.

TLC: R_f = 0.67 (Hexane/EtOAc = 3:1) [UV, KMnO₄].


¹H NMR (400 MHz, CDCl₃) δ 8.08 – 7.95 (m, 2H), 7.39 – 7.19 (m, 5H), 7.00 (*virt. td*, $J \geq 7.4, 1.1$ Hz, 1H), 4.49 (*virt. td*, $J \geq 10.4, 5.1$ Hz, 1H), 4.14 – 4.05 (m, 1H), 2.47 (*virt. dd*, $J \geq 13.7, 5.1$ Hz, 1H), 2.39 (s, 3H), 1.81 (ddd, $J = 13.7, 10.4, 8.3$ Hz, 1H), 1.04 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 174.0, 159.4, 145.0, 134.7, 133.0, 130.6, 129.8, 128.1, 124.2, 123.7, 119.8, 93.4, 80.7, 55.8, 29.7, 26.2, 21.7.

IR (KBr/cm⁻¹) 3068.5, 2978.9, 2928.8, 1632.6, 1601.1, 1366.3, 1169.7, 751.9.

HRMS (ESI): C₂₁H₂₅N₂O₄S [(M+H)⁺]: calcd.: 401.1530; found: 401.1534.

3a-(*tert*-Butylperoxy)-1-(methylsulfonyl)-1,2,3,3a-tetrahydropyrrolo[2,3-b]indole 2b



Compound **2b** was synthesized following the *general procedure*.

A white solid, 44.1 mg, 68% yield.

m.p.: 165 – 170 °C.

TLC: $R_f = 0.28$ (Hexane/EtOAc = 3:1) [UV, KMnO₄].


¹H NMR (400 MHz, CDCl₃) δ 7.37 – 7.30 (m, 3H), 7.14 – 7.00 (m, 1H), 4.56 (*virt.* td, $J \geq 10.1$, 5.0 Hz, 1H), 4.33 – 4.20 (m, 1H), 3.28 (s, 3H), 2.62 (*virt.* dd, $J \geq 13.6$, 5.0 Hz, 1H), 2.13 (*virt.* dt, $J \geq 13.6$, 10.1 Hz, 1H), 1.09 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 174.4, 159.0, 132.9, 130.7, 124.4, 124.1, 119.7, 93.4, 80.9, 56.2, 38.9, 30.3, 26.3.

IR (ATR/cm⁻¹) 2977.3, 2926.7, 1636.2, 1601.7, 1455.4, 1360.0, 1265.3, 1164.2, 1100.5, 998.4, 965.1, 874.3, 764.3.

HRMS (ESI): C₁₅H₂₀N₂NaO₄S [(M+Na)⁺]: calcd.: 347.1036; found: 347.1037.

3a-(*tert*-Butylperoxy)-1-((4-nitrophenyl)sulfonyl)-1,2,3,3a-tetrahydropyrrolo[2,3-b]indole 2c



Compound **2c** was synthesized following the *general procedure*.

A white solid, 47.5 mg, 55% yield.

m.p.: 166 – 170 °C.

TLC: $R_f = 0.71$ (Hexane/EtOAc = 3:1) [UV, KMnO₄].


¹H NMR (400 MHz, CDCl₃) δ 8.41 – 8.36 (m, 4H), 7.37 – 7.30 (m, 3H), 7.05 (t, $J = 7.2$ Hz, 1H), 4.57 (*virt.* td, $J \geq 11.2$, 5.2 Hz, 1H), 4.21 – 4.12 (m, 1H), 2.51 (*virt.* dd, $J \geq 11.2$, 5.2 Hz, 1H), 1.94 – 1.82 (m, 1H), 1.03 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 173.5, 158.8, 150.9, 143.2, 132.8, 130.8, 129.5, 124.4, 124.4, 124.4, 120.1, 93.1, 80.9, 56.3, 29.6, 26.2.

IR (ATR/cm⁻¹) 3105.8, 2981.2, 2930.3, 1636.1, 1602.8, 1533.1, 1371.7, 1262.8, 1175.1, 1095.7, 999.7, 857.2, 741.1, 623.3, 564.1.

HRMS (ESI): C₂₀H₂₁N₃NaO₆S [(M+Na)⁺]: calcd.: 454.1043; found: 454.1045.

3a-(*tert*-Butylperoxy)-4-methyl-1-tosyl-1,2,3,3a-tetrahydropyrrolo[2,3-b]indole 2d



Compound **2d** was synthesized following the *general procedure*.

A white solid, 42.3 mg, 51% yield.

m.p.: 163 – 168 °C.

TLC: $R_f = 0.66$ (Hexane/EtOAc = 3:1) [UV, KMnO₄].


¹H NMR (400 MHz, CDCl₃) δ 8.05 – 8.03 (m, 2H), 7.32 – 7.30 (m, 2H), 7.18 – 7.17 (m, 2H), 6.86 – 6.74 (m, 1H), 4.52 (*virt.* td, $J \approx 10.1, 5.2$ Hz, 1H), 4.12 (*virt.* t, $J \approx 10.1$ Hz, 1H), 2.50 – 2.42 (m, 1H), 2.41 (s, 3H), 2.26 (s, 3H), 1.96 – 1.84 (m, 1H), 1.04 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 174.2, 159.4, 145.0, 135.0, 134.9, 130.9, 130.6, 129.8, 128.1, 125.5, 117.3, 93.3, 80.6, 56.0, 29.6, 26.2, 21.7, 18.0.

IR (ATR/cm⁻¹) 3049.4, 2981.0, 2924.7, 1628.9, 1594.5, 1432.6, 1361.3, 1240.0, 1171.1, 1090.5, 1050.6, 991.4, 910.6, 809.5, 669.2, 569.8.

HRMS (ESI): C₂₂H₂₆N₂NaO₄S [(M+Na)⁺]: calcd.: 437.1505; found: 437.1509.

3a-(*tert*-Butylperoxy)-5-fluoro-1-tosyl-1,2,3,3a-tetrahydropyrrolo[2,3-b]indole 2e



Compound **2e** was synthesized following the *general procedure*.

A white solid, 57.7 mg, 67% yield.

m.p.: 148 – 153 °C.

TLC: $R_f = 0.57$ (Hexane/EtOAc = 3:1) [UV, KMnO₄].


¹H NMR (400 MHz, CDCl₃) δ 8.04 – 8.02 (m, 2H), 7.37 – 7.27 (m, 3H), 7.04 – 6.92 (m, 2H), 4.47 (m, 1H), 4.15 – 4.06 (m, 1H), 2.51 – 2.44 (m, 1H), 2.42 (s, 3H), 1.90 – 1.77 (m, 1H), 1.05 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 173.6, 159.9 (d, $J = 243.2$ Hz), 155.0, 145.1, 134.7, 134.5 (d, $J = 8.5$ Hz), 129.9, 128.1, 120.2 (d, $J = 8.3$ Hz), 116.5 (d, $J = 23.2$ Hz), 112.4 (d, $J = 25.2$ Hz), 93.7 – 92.9 (m), 80.9, 55.6, 29.7, 26.2, 21.7.

IR (ATR/cm⁻¹) 2978.6, 2930.0, 1604.0, 1479.0, 1366.4, 1285.7, 1172.7, 1143.4, 1095.5, 1002.5, 813.0, 675.7, 581.7, 548.3.

HRMS (ESI): C₂₁H₂₃FN₂NaO₄S [(M+Na)⁺]: calcd.: 441.1255; found: 441.1259.

3a-(*tert*-Butylperoxy)-5-methoxy-1-tosyl-1,2,3,3a-tetrahydropyrrolo[2,3-b]indole 2f



Compound **2f** was synthesized following the *general procedure*.

A white solid, 51.1 mg, 61% yield.

m.p.: 147 – 150 °C.

TLC: $R_f = 0.47$ (Hexane/EtOAc = 3:1) [UV, KMnO₄].


¹H NMR (400 MHz, CDCl₃) δ 8.04 – 8.02 (m, 2H), 7.32 – 7.30 (m, 2H), 7.26 (d, $J = 8.3$ Hz, 1H), 6.90 (s, 1H), 6.80 (d, $J = 8.3$ Hz, 1H), 4.51 – 4.39 (m, 1H), 4.08 (*virt. t*, $J \geq 9.2$ Hz, 1H), 3.77 (s, 3H), 2.45 (*virt. dd*, $J \geq 13.4$, 5.1 Hz, 1H), 2.41 (s, 3H), 1.85 – 1.77 (m, 1H), 1.06 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 172.4, 156.7, 152.4, 144.9, 134.8, 134.3, 129.8, 128.0, 119.9, 114.1, 112.0, 93.4, 80.7, 55.8, 55.5, 29.6, 26.2, 21.7.

IR (ATR/cm⁻¹) 2958.3, 2926.9, 1634.2, 1468.1, 1367.3, 1264.7, 1170.8, 1095.9, 1017.4, 926.1, 816.8, 668.9, 574.0, 548.0.

HRMS (ESI): C₂₂H₂₆N₂NaO₅S [(M+Na)⁺]: calcd.: 453.1455; found: 453.1455.

3a-(*tert*-butylperoxy)-5-chloro-1-tosyl-1,2,3,3a-tetrahydropyrrolo[2,3-b]indole 2g



Compound **2g** was synthesized following the *general procedure*.

A white solid, 61.7 mg, 71% yield.

m.p.: 147.9 – 155.1°C.

TLC: $R_f = 0.72$ (Hexane/EtOAc = 3:1) [UV, KMnO₄].


¹H NMR (400 MHz, CDCl₃) δ 8.02 (d, $J = 8.0$ Hz, 2H), 7.33 (d, $J = 8.0$ Hz, 2H), 7.26 (m, 3H), 4.48 (*virt. td*, $J \geq 10.2$, 5.1 Hz, 1H), 4.11 (*virt. t*, $J \geq 9.1$ Hz, 1H), 2.48 – 2.43 (m, 1H), 2.42 (s, 3H), 1.87 – 1.79 (m, 1H), 1.05 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 173.9, 157.7, 145.1, 134.5, 134.4, 130.3, 129.8, 129.1, 127.9, 124.6, 120.4, 93.2, 80.9, 55.6, 29.6, 26.1, 21.6.

IR (ATR/cm⁻¹) 2980.6, 2928.5, 1632.5, 1596.6, 1448.5, 1367.7, 1254.6, 1172.1, 1095.4, 915.6, 817.7, 673.9, 580.5, 547.3.

HRMS (ESI): C₂₁H₂₃³⁵ClN₂NaO₄S [(M+Na)⁺]: calcd.: 457.0959; found: 457.0961.

5-Bromo-3a-(*tert*-butylperoxy)-1-tosyl-1,2,3,3a-tetrahydropyrrolo[2,3-b]indole 2h



Compound **2h** was synthesized following the *general procedure*.

A white solid, 74.8 mg, 78% yield.

m.p.: 159 – 165 °C.

TLC: $R_f = 0.65$ (Hexane/EtOAc = 3:1) [UV, KMnO₄].

¹H NMR (400 MHz, CDCl₃) δ 8.03 – 8.01 (m, 2H), 7.48 – 7.37 (m, 2H), 7.34 – 7.32 (m, 2H), 7.22 (d, $J = 7.7$ Hz, 1H), 4.48 (*virt. td*, $J \geq 10.4, 5.2$ Hz, 1H), 4.11 (*virt. t*, $J \geq 9.2$ Hz, 1H), 2.48 – 4.46 (m, 1H), 2.41 (s, 3H), 1.88 – 1.78 (m, 1H), 1.05 (s, 9H).


¹³C NMR (101 MHz, CDCl₃) δ 174.0, 158.3, 145.2, 134.9, 134.6, 133.4, 129.9, 128.0, 127.5, 121.1, 116.8, 93.3, 81.0, 55.8, 29.7, 26.2, 21.7.

IR (ATR/cm⁻¹) 2979.6, 2927.5, 1632.5, 1596.8, 1442.8, 1368.7, 1254.4, 1171.1, 1095.4, 915.2, 818.8, 673.8, 581.6, 547.7.

HRMS (ESI): C₂₁H₂₃⁷⁹BrN₂NaO₄S [(M+Na)⁺]: calcd.: 501.0454; found: 501.0454.

HRMS (ESI): C₂₁H₂₃⁸¹BrN₂NaO₄S [(M+Na)⁺]: calcd.: 503.0433; found: 503.0437.

3a-(*tert*-Butylperoxy)-5-methyl-1-tosyl-1,2,3,3a-tetrahydropyrrolo[2,3-b]indole 2i



Compound **2i** was synthesized following the *general procedure*.

A white solid, 60.5 mg, 73% yield.

m.p.: 143 – 146 °C.

TLC: $R_f = 0.41$ (Hexane/EtOAc = 3:1) [UV, KMnO₄].


¹H NMR (400 MHz, CDCl₃) δ 8.03 – 8.01 (m, 2H), 7.30 – 7.26 (m, 3H), 6.90 (s, 1H), 6.80 (d, $J = 8.1$ Hz, 1H), 4.53 – 4.39 (m, 1H), 4.08 (*virt. t*, $J \geq 9.1$ Hz, 1H), 3.77 (s, 3H), 2.45 (*virt. dd*, $J \geq 13.9, 4.8$ Hz, m, 1H), 2.40 (s, 3H), 1.86 – 1.75 (m, 1H), 1.06 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 172.4, 156.7, 152.4, 144.9, 134.8, 134.3, 129.8, 128.0, 119.8, 114.1, 112.0, 93.3, 80.7, 55.8, 55.5, 29.6, 26.2, 21.7.

IR (ATR/cm⁻¹) 2980.5, 1634.1, 1468.3, 1367.4, 1264.6, 1170.9, 1095.8, 1017.0, 925.4, 816.4, 731.8, 668.6, 547.9.

HRMS (ESI): C₂₂H₂₆N₂NaO₄S [(M+Na)⁺]: calcd.: 437.1505; found: 437.1507.

3a-(*tert*-Butylperoxy)-6-fluoro-1-tosyl-1,2,3,3a-tetrahydropyrrolo[2,3-b]indole 2j



Compound **2j** was synthesized following the *general procedure*.

A white solid, 52.7 mg, 63% yield.

m.p.: 146 – 149 °C.

TLC: $R_f = 0.67$ (Hexane/EtOAc = 3:1) [UV, KMnO₄].


¹H NMR (400 MHz, CDCl₃) δ 8.04 – 8.02 (m, 2H), 7.34 – 7.32 (m, 2H), 7.20 (s, 1H), 7.07 (d, $J = 9.3$ Hz, 1H), 6.69 (t, $J = 8.7$ Hz, 1H), 4.50 (*virt. td*, $J \cong 10.5, 10.1, 4.8$ Hz, 1H), 4.12 (*virt. t*, $J \cong 9.1$ Hz, 1H), 2.47 (s, 1H), 2.42 (s, 3H), 1.92 – 1.66 (m, 1H), 1.04 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 175.5, 164.6 (d, $J = 246.9$ Hz), 161.4 (d, $J = 11.8$ Hz), 145.3, 134.6, 129.9, 128.5 (d, $J = 2.6$ Hz), 128.1, 124.8 (d, $J = 10.0$ Hz), 109.8 (d, $J = 22.9$ Hz), 108.1 (d, $J = 25.0$ Hz), 92.8, 80.8, 55.9, 29.8, 26.2, 21.7.

IR (ATR/cm⁻¹) 2979.5, 2927.5, 1599.4, 1470.8, 1367.5, 1281.5, 1173.1, 1096.6, 1004.2, 904.3, 813.3, 674.9, 579.7, 547.4.

HRMS (ESI): C₂₁H₂₃FN₂NaO₄S [(M+Na)⁺]: calcd.: 441.1255; found: 441.1259.

3a-(*tert*-Butylperoxy)-6-chloro-1-tosyl-1,2,3,3a-tetrahydropyrrolo[2,3-b]indole 2k



Compound **2k** was synthesized following the *general procedure*.

A white solid, 65.3 mg, 75% yield.

m.p.: 148 – 154 °C.

TLC: $R_f = 0.74$ (Hexane/EtOAc = 3:1) [UV, KMnO₄].


¹H NMR (400 MHz, CDCl₃) δ 8.04 – 8.02 (m, 2H), 7.34 – 7.32 (m, 3H), 7.18 (d, $J = 7.9$ Hz, 1H), 6.99 (d, $J = 7.3$ Hz, 1H), 4.50 (*virt. td*, $J \cong 10.0, 5.0$ Hz, 1H), 4.11 (*virt. t*, $J \cong 9.0$ Hz, 1H), 2.51 – 2.44 (m, 1H), 2.42 (s, 3H), 1.88 – 1.76 (m, 1H), 1.05 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 175.1, 160.7, 145.3, 136.2, 134.6, 131.3, 129.9, 128.1, 124.7, 123.6, 120.4, 93.0, 80.9, 55.9, 29.9, 26.2, 21.7.

IR (ATR/cm⁻¹) 2980.7, 2929.3, 1632.5, 1596.6, 1449.3, 1366.6, 1281.2, 1172.5, 1095.3, 1003.2, 870.3, 814.9, 673.9, 576.8, 547.3.

HRMS (ESI): C₂₁H₂₃³⁵ClN₂NaO₄S [(M+Na)⁺]: calcd.: 457.0959; found: 457.0963.

6-Bromo-3a-(*tert*-butylperoxy)-1-tosyl-1,2,3,3a-tetrahydropyrrolo[2,3-b]indole 2l



Compound **2l** was synthesized following the *general procedure*.

A white solid, 65.2 mg, 68% yield.

m.p.: 156 – 160 °C.

TLC: $R_f = 0.71$ (Hexane/EtOAc = 3:1) [UV, KMnO₄].

¹H NMR (400 MHz, CDCl₃) δ 8.03 – 8.01 (m, 2H), 7.49 (s, 1H), 7.34 – 7.32 (m, 2H), 7.17 – 7.13 (m, 2H), 4.51 (*virt. td*, $J \cong 10.1, 5.1$ Hz, 1H), 4.11 (*virt. t*, $J \cong 8.9$ Hz, 1H), 2.52 – 2.44 (m, 1H), 2.42 (s, 3H), 1.87 – 1.75 (m, 1H), 1.05 (s, 9H).


¹³C NMR (101 MHz, CDCl₃) δ 175.0, 160.8, 145.3, 134.6, 131.8, 129.9, 128.1, 126.5, 125.1, 124.2, 123.2, 93.1, 81.0, 55.9, 29.8, 26.2, 21.7.

IR (ATR/cm⁻¹) 2981.5, 2928.4, 1632.9, 1595.9, 1447.8, 1365.5, 1282.1, 1171.1, 1097.9, 1003.4, 871.4, 815.5, 674.8, 577.2.

HRMS (ESI): C₂₁H₂₃⁷⁹BrN₂NaO₄S [(M+Na)⁺]: calcd.: 501.0454; found: 501.0450.

HRMS (ESI): C₂₁H₂₃⁸¹BrN₂NaO₄S [(M+Na)⁺]: calcd.: 503.0433; found: 503.0429.

3a-(*tert*-Butylperoxy)-6-methoxy-1-tosyl-1,2,3,3a-tetrahydropyrrolo[2,3-b]indole 2m



Compound **2m** was synthesized following the *general procedure*.

A white solid, 63.7 mg, 74% yield.

m.p.: 165 – 168 °C.

TLC: $R_f = 0.40$ (Hexane/EtOAc = 3:1) [UV, KMnO₄].


¹H NMR (400 MHz, CDCl₃) δ 8.04 – 8.02 (m, 2H), 7.33 – 7.31 (m, 2H), 7.16 (d, $J = 8.0$ Hz, 1H), 7.02 – 6.91 (m, 1H), 6.51 (d, $J = 7.9$ Hz, 1H), 4.48 (*virt. td*, $J \cong 10.1, 5.1$ Hz, 1H), 4.09 (*virt. t*, $J \cong 9.2$ Hz, 1H), 3.81 (s, 3H), 2.49 – 2.43 (m, 1H), 2.41 (s, 3H), 1.81 (*virt. dt*, $J \cong 13.3, 10.1$ Hz, 1H), 1.05 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 175.1, 162.0, 161.3, 145.1, 134.8, 129.8, 128.1, 124.9, 124.6, 108.3, 106.7, 93.1, 80.7, 55.9, 55.5, 30.0, 26.3, 21.7.

IR (ATR/cm⁻¹) 2981.4, 2930.4, 1636.8, 1605.8, 1460.6, 1369.2, 1262.0, 1169.9, 1096.6, 929.7, 819.4, 733.1, 669.1, 592.2, 551.1.

HRMS (ESI): C₂₂H₂₆N₂NaO₅S [(M+Na)⁺]: calcd.: 453.1455; found: 453.1455.

3a-(*tert*-Butylperoxy)-6-methyl-1-tosyl-1,2,3,3a-tetrahydropyrrolo[2,3-b]indole 2n



Compound **2n** was synthesized following the *general procedure*.

A white solid, 44.8 mg, 54% yield.

m.p.: 147 – 153 °C.

TLC: $R_f = 0.73$ (Hexane/EtOAc = 3:1) [UV, KMnO₄].


¹H NMR (400 MHz, CDCl₃) δ 8.05 – 8.03 (m, 2H), 7.32 – 7.30 (m, 2H), 7.18 (s, 1H), 7.15 (d, $J = 7.4$ Hz, 1H), 6.82 (d, $J = 7.1$ Hz, 1H), 4.49 (*virt. td*, $J \geq 10.1, 5.2$ Hz, 1H), 4.08 (*virt. t*, $J \geq 9.1$ Hz, 1H), 2.46 (*virt. dd*, $J \geq 13.7, 4.9$ Hz, 1H), 2.41 (s, 3H), 2.35 (s, 3H), 1.83 – 1.73 (m, 1H), 1.06 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 174.2, 159.6, 145.0, 140.9, 134.8, 130.0, 129.8, 128.1, 124.2, 123.9, 120.8, 93.2, 80.7, 55.9, 29.9, 26.3, 21.9, 21.7.

IR (ATR/cm⁻¹) 2979.8, 2927.0, 1604.0, 1456.3, 1364.8, 1262.8, 1172.0, 1094.6, 1004.2, 814.5, 675.1, 578.1, 547.7.

HRMS (ESI): C₂₂H₂₆N₂NaO₄S [(M+Na)⁺]: calcd.: 437.1505; found: 437.1509.

3a-(*tert*-Butylperoxy)-7-methyl-1-tosyl-1,2,3,3a-tetrahydropyrrolo[2,3-b]indole 2o



Compound **2o** was synthesized following the *general procedure*.

A white solid, 51.4 mg, 62% yield.

m.p.: 140 – 146 °C.

TLC: $R_f = 0.82$ (Hexane/EtOAc = 3:1) [UV, KMnO₄].


¹H NMR (400 MHz, CDCl₃) δ 8.08 (d, $J = 8.0$ Hz, 2H), 7.30 (d, $J = 8.0$ Hz, 2H), 7.11 (d, $J = 6.9$ Hz, 2H), 6.91 (t, $J = 6.9$ Hz, 1H), 4.53 (*virt. td*, $J \geq 10.2, 5.2$ Hz, 1H), 4.10 (*virt. t*, $J \geq 9.3$ Hz, 1H), 2.48 (s, 3H), 2.40 (s, 3H), 1.79 – 1.70 (m, 1H), 1.67 (s, 1H), 1.09 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 172.8, 157.3, 145.0, 134.5, 133.0, 132.1, 129.6, 129.2, 128.4, 123.5, 121.7, 93.4, 80.7, 67.2, 56.0, 26.3, 21.7, 16.8.

IR (ATR/cm⁻¹) 3053.8, 2977.8, 2926.4, 1632.3, 1599.5, 1459.3, 1367.8, 1276.1, 1170.5, 1095.8, 926.5, 759.2, 669.9, 588.5, 547.4.

HRMS (ESI): C₂₂H₂₆N₂NaO₄S [(M+Na)⁺]: calcd.: 437.1505; found: 437.1508.

**Methyl 3a-(*tert*-butylperoxy)-1-tosyl-1,2,3,3a-tetrahydropyrrolo[2,3-b]indole-2-carboxylate
2p**



Compound **2p** was synthesized following the *general procedure*.

A white solid, 73.4 mg, 80% yield. The product contains a mixture of two inseparable diastereoisomers (1.5:1).

TLC: $R_f = 0.55$ (Hexane/EtOAc = 3:1) [UV, KMnO₄].

Minor product:

¹H NMR (400 MHz, CDCl₃) δ 8.13 – 8.11 (m, 2H), 7.36 (m, 5H), 7.04 (d, $J = 8.1$ Hz, 1H), 5.29 – 5.22 (m, 1H), 3.84 (s, 3H), 3.00 – 2.91 (m, 1H), 2.42 (s, 3H), 2.21 (m, 1H), 0.91 (s, 9H).

¹³C NMR (101 MHz, CDCl₃) δ 173.2, 169.8, 159.7, 144.9, 136.0, 132.6, 130.9, 129.6, 128.7, 124.5, 124.2, 120.3, 92.2, 80.7, 68.8, 52.9, 32.6, 26.0, 21.7.

Major product:


¹H NMR (400 MHz, CDCl₃) δ 8.04 (d, $J = 8.1$ Hz, 3H), 7.33 – 7.21 (m, 7.5H), 6.99 (d, $J = 8.1$ Hz, 1.5H), 5.20 (m, 1.5H), 3.75 (s, 4.5H), 2.88 (m, 1.5H), 2.42 (s, 4.5H), 2.04 (m, 1.5H), 0.91 (s, 13.5H).

¹³C NMR (101 MHz, CDCl₃) δ 173.0, 170.0, 159.2, 145.2, 134.9, 132.7, 130.7, 129.6, 128.2, 124.4, 123.8, 119.9, 92.7, 80.7, 68.6, 52.9, 35.5, 26.1, 21.7.

IR (ATR/cm⁻¹) 3063.9, 2981.1, 1757.5, 1637.9, 1601.5, 1449.0, 1365.9, 1171.0, 1090.4, 912.6, 810.1, 733.5, 666.4, 571.0.


HRMS (ESI): C₂₃H₂₆N₂NaO₆S [(M+Na)⁺]: calcd.: 481.1404; found: 481.1407.

Reduction procedure:



A 50 ml round bottom flask was charged with substrate **2a** (0.2 mmol, 1.0 equiv) and THF (8.0 mL), then NaBH₄ (3.0 equiv) was added portionwise at room temperature and the mixture was stirred until the starting material was disappeared and monitored by analysis TLC (1 h). Saturated aqueous NH₄Cl solution (20 mL) was added to the mixture carefully, extracted with EtOAc (3 × 10 mL). The combined organic layers were dried over Na₂SO₄, filtered, concentrated under reduced pressure and the residue was purified by chromatography on silica gel (eluent: Hexane/EtOAc, 30:1 to 10:0) to afford peroxypryroloindoline **3a**.

3a-(*tert*-Butylperoxy)-1-tosyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole 3a



A white solid, 70.0 mg, 87% yield.

m.p.: 98 – 101 °C.

TLC: $R_f = 0.71$ (Hexane/EtOAc = 3:1) [UV, KMnO₄].

¹H NMR (400 MHz, CDCl₃) δ 7.79 – 7.77 (m, 2H), 7.34 – 7.32 (m, 2H), 7.12 – 7.22 (m, 1H), 6.76 (*virt.* t, $J \approx 7.4$ Hz, 1H), 6.65 (d, $J = 8.0$ Hz, 1H), 5.43 (d, $J = 1.8$ Hz, 1H), 4.91 (s, 1H), 3.38 (ddd, $J = 10.0, 8.0, 5.0$ Hz, 1H), 3.32 – 3.21 (m, 1H), 2.54 (*virt.* dt, $J \approx 12.5, 8.0$ Hz, 1H), 2.43 (s, 3H), 2.16 (ddd, $J = 12.5, 6.8, 5.0$ Hz, 1H), 1.06 (s, 9H).


¹³C NMR (101 MHz, CDCl₃) δ 150.2, 143.8, 135.1, 130.9, 129.8, 127.7, 126.0, 124.8, 119.1, 110.3, 97.9, 80.1, 79.4, 47.4, 33.9, 26.5, 21.6.

IR (KBr/cm⁻¹) 3438.2, 3057.5, 2976.1, 2889.5, 1613.0, 1339.5, 1164.0, 754.1.


HRMS (ESI): C₂₁H₂₆N₂NaO₄S [(M+Na)⁺]: calcd.: 425.1505; found: 425.1504.

(D) Mass Analysis of Reaction Mixtures

MS analysis of reaction mixture of 1a



MS analysis of reaction mixture of substrate 4



(E) ^1H and ^{13}C NMR Spectra Data of All Products

